Strategic partnerships Position Longeveron as a partner for biopharma and medtech companies seeking regenerative therapies by highlighting ongoing Phase 2b HLHS trial, the Alzheimer's program with RMAT designation, and potential for co-development or licensing of laromestrocel across aging-related conditions.

Clinical momentum Leverage recent AAIC data presentations and ongoing Phase 2b pivotal HLHS study to initiate conversations with researchers, CROs, and academic medical centers about trial collaboration, patient access pathways, and real-world evidence generation.

Regulatory edge Emphasize EMA SME status and RMAT designation as market access accelerators to prospective partners and investors, framing potential faster regulatory pathways and prioritized engagement in Europe.

Orphan and aging focus Target rare pediatric HLHS programs and aging-related frailty opportunities by mapping laromestrocel MOAs to unmet needs in pediatric congenital conditions and elderly cohorts, highlighting multi-indication applicability to attract strategic collaborations.

Financial leverage Use a clear funding and cash runway narrative showing $69M raised and a multiprogram pipeline to engage investors and partners in co-funding, milestone-driven deals, and upfront royalties tied to pivotal trial outcomes.